Mirati Therapeutics (MRTX) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 41

Mirati Therapeutics (MRTX) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 41 from a previous price target of $45 . Wedbush advised their investors in a research report released on May 9, 2016.

Many Wall Street Analysts have commented on Mirati Therapeutics. Sun Trust Rbsn Humphrey Initiated Mirati Therapeutics on Mar 2, 2016 to “Buy”, Price Target of the shares are set at $32.Mirati Therapeutics was Resumed by Jefferies to “Buy” on Feb 17, 2016.

Mirati Therapeutics closed down -3 points or -15.87% at $15.9 with 5,03,753 shares getting traded on Friday. Post opening the session at $18.01, the shares hit an intraday low of $14.5901 and an intraday high of $18.1699 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Jan 19, 2016, Mark J Gergen (Executive VP, COO) sold 10,000 shares at $25.92 per share price. According to the SEC, on May 27, 2015, Jamie Christensen (SVP & Chief Scientific Officer) sold 4,750 shares at $28.07 per share price.

Mirati Therapeutics

Leave a Reply

Mirati Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Mirati Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.